Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955477 | 0.90 | CPT1A (0.54) | HDAC1HDAC6PPARGHTR6CYP2C9 | |
| SCHEMBL9372377 | 0.90 | CPT1A (0.54) | HDAC1HDAC6PPARGHTR6CYP2C9 | |
| SCHEMBL31279908 | 0.89 | HTR6 (0.64) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL2509440 | 0.89 | HTR6 (0.64) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL15188844 | 0.86 | RAPGEF4 (0.76) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL1780727 | 0.86 | RAPGEF4 (0.74) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL20488722 | 0.86 | RAPGEF4 (0.60) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL27819639 | 0.85 | RAPGEF4 (0.58) | HDAC1HDAC6PPARGRAPGEF4HDAC3 | |
| SCHEMBL31159433 | 0.84 | HDAC1 (0.79) | HDAC1HDAC6PPARGHDAC3HDAC8 | |
| SCHEMBL8116244 | 0.82 | PPARG (0.61) | HDAC1HDAC6PPARGRAPGEF4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582485-B | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| CN-110582485-A | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2019-12-17 | — | — | CN | disclosed |
| WO-2018158212-A1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-07 | — | — | WO | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1210343-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012187-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-02-22 | — | — | WO | disclosed |
| EP-0290145-B1 | Aliphatic carboxamides | ICI AMERICA INC (US) | 1994-10-26 | — | — | EP | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0290145-A1 | Aliphatic carboxamides | ZENECA INC. (US) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | BRD3, BRD4, BRPF3 | HDAC1 16/4885HDAC6 22/4885PPARG 27/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | HDAC1 84/4885HDAC6 302/4885PPARG 3723/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | HDAC1 946/4885HDAC6 979/4885PPARG 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.